View More Recent Stories

Oct 23, 2018 04:05PM Five Prime Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 6
Oct 16, 2018 09:03AM Five Prime Therapeutics (FPRX) Commences Patient Dosing in The Dose Exploration Cohort of Ongoing Phase 1 Trial FPA150
Oct 16, 2018 09:00AM Five Prime Therapeutics Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
Oct 1, 2018 08:02AM Five Prime Therapeutics (FPRX), Zai Lab Limited (ZLAB) Report First Patient Dosed in Phase 3 FIGHT Pivotal Trial of Bemarituzumab (FPA144)
Oct 1, 2018 08:00AM Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Sep 26, 2018 04:05PM Five Prime Therapeutics to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology
Sep 10, 2018 09:04AM Five Prime Therapeutics (FPRX) Reports Complete Phase 1 Safety Lead-In and Initiates Phase 3 of FIGHT Phase 1/3 Clinical Trial of Bemarituzumab (FPA144)
Sep 10, 2018 09:00AM Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Aug 30, 2018 04:05PM Five Prime Therapeutics to Present at 2018 Wells Fargo Healthcare Conference
Aug 8, 2018 04:05PM Five Prime Therapeutics Announces Second Quarter 2018 Financial Results
Jul 26, 2018 04:05PM Five Prime Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 8
Jun 11, 2018 04:05PM Five Prime Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Jun 4, 2018 06:45AM Five Prime Therapeutics (FPRX) Announces Bemarituzumab Trial-in-Progress Poster at 2018 ASCO Meeting
Jun 3, 2018 09:00AM Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting
May 31, 2018 04:05PM Five Prime Therapeutics to Present at Jefferies 2018 Global Healthcare Conference
May 30, 2018 04:09PM Five Prime Therapeutics (FPRX) Announces Pact with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates
May 30, 2018 04:05PM Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates
May 29, 2018 04:05PM Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018
May 15, 2018 04:05PM Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer
May 8, 2018 04:05PM Five Prime Therapeutics Announces First Quarter 2018 Financial Results
Apr 25, 2018 03:01PM Five Prime to Present at 2018 ASCO Annual Meeting
Apr 24, 2018 04:05PM Five Prime Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on May 8
Apr 16, 2018 05:55AM Five Prime Therapeutics (FPRX) Announces Data on B7-H4 Therapeutic Antibody at 2018 AACR Annual Meeting
Apr 15, 2018 02:50PM Five Prime Presents on Novel B7-H4 Therapeutic Antibody at the 2018 AACR Annual Meeting
Apr 3, 2018 07:00AM Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab
Mar 28, 2018 04:05PM Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
Mar 27, 2018 04:05PM Five Prime Therapeutics Announces Oral Presentation on FPA150 at the 2018 AACR Annual Meeting
Mar 19, 2018 09:05AM Five Prime Therapeutics (FPRX) Licenses New Drug Target to UCB
Mar 19, 2018 09:00AM Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform
Mar 13, 2018 04:05PM Five Prime Therapeutics Announces Executive Change
Mar 6, 2018 04:05PM Five Prime Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
Feb 27, 2018 04:05PM Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results
Feb 13, 2018 04:05PM Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
Feb 8, 2018 04:10PM Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
Jan 25, 2018 04:15PM Five Prime Therapeutics (FPRX) Announces $25 Million Payment by Bristol-Myers Squibb (BMY) for Cabiralizumab Development Milestone
Jan 25, 2018 04:05PM Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
Jan 8, 2018 08:34AM Five Prime Therapeutics (FPRX) Secures $5M IND Milestone Payment from Bristol-Myers Squibb (BMY) Under Immune Checkpoint Pathways Discovery Collaboration; BMY to Extend Term for 2nd Time
Jan 8, 2018 08:30AM Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Col
Nov 9, 2017 08:09AM Bristol-Myers Squibb (BMY) & Five Prime (FPRX) Announce Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Nov 9, 2017 08:00AM Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Oct 14, 2016 08:30AM Cancer Immunotherapy ETF Celebrates One-Year Anniversary
Sep 16, 2016 10:00AM Five Prime Therapeutics (Nasdaq: FPRX) to Ring The Nasdaq Stock Market Opening Bell
Oct 15, 2015 04:00AM Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Oct 15, 2015 04:00AM Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Oct 15, 2015 04:00AM Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Mar 17, 2014 06:59AM Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways
View More Recent Stories